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ABSTRACT
Over the last decades, the genus Streptomyces has
stirred huge interest in the scientific community as
a source of bioactive compounds. The majority of
all known antibiotics is isolated from these bac-
terial strains, as well as a variety of other drugs
such as antitumor agents, immunosuppressants and
antifungals. To the best of our knowledge, Strep-
tomeDB was the first database focusing on com-
pounds produced by streptomycetes. The new ver-
sion presented herein represents a major step for-
ward: its content has been increased to over 4000
compounds and more than 2500 host organisms.
In addition, we have extended the background in-
formation and included hundreds of new manually
curated references to literature. The latest update
features a unique scaffold-based navigation system,
which enables the exploration of the chemical diver-
sity of StreptomeDB on a structural basis. We have
included a phylogenetic tree, based on 16S rRNA se-
quences, which comprises more than two-thirds of
the included host organisms. It enables visualizing
the frequency, appearance, and persistence of com-
pounds and scaffolds in an evolutionary context. Ad-
ditionally, we have included predicted MS- and NMR-
spectra of thousands of compounds for assignment




The growing number of annotated natural products (NPs)
in databases, such as Super Natural II (∼326 000 com-
pounds; 2D structures; physicochemical properties; pre-
dicted toxicity class; potential vendors) (1), KNApSAcK
(∼51 000 metabolites; ∼111 000 metabolite-species pairs)
(2), UNPD (∼229 000 compounds; 3D structures) (3) or
NORINE (∼1200 NRPs) (4) reflects the increasing inter-
est in these molecules. StreptomeDB is, to the best of our
knowledge, the biggest compilation of NPs produced by
streptomycetes. Its content has been collected from thou-
sands of abstracts and full papers by text mining methods
and extensivemanual curation. In addition, it includes com-
prehensive background information such as host organ-
isms, predicted physicochemical properties, synthesis routes
and biological activities.
Streptomyces is a genus of Gram-positive actinobacteria.
They can be found all around the world in soil samples and
successfully inhabit many terrestrial and aquatic niches (5).
Since the discovery of streptomycin by Albert Schatz in the
group of Selman Waksman in 1943 (6), they have become
one of the best studied bacterial genera. Over 60% of all
known antibiotics have been isolated from streptomycetes
(5). Many of these compounds are approved drugs, such as
the well-known agents tetracycline, daptomycin and chlo-
ramphenicol (7). Besides antibiotics, there is a rich diver-
sity of other secondary metabolites with a plethora of dif-
ferent biological activities and therapeutic potential exclu-
sively produced by streptomycetes. Blockbuster drugs like
the anti-parasitic agent avermectin, the immunosuppres-
sant rapamycin or the lipase inhibitor lipstatin are just a few
examples (8,9,10). There is also a large number of potential
antibiotics or other bioactive compounds found in Strep-
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tomeDB which are not in clinical use (11). As the recent
development of highly effective griselimycin analogs shows
(12), these molecules can be considered as possible corner-
stones for the future development of semi-synthetic drugs
(13).
A common starting point of a modern drug discovery
campaign is an in silico high-throughput screening for small
molecules or fragments that can interact with a therapeutic
target of interest (14). The method strongly relies on high
quality and diverse compound libraries like StreptomeDB.
Although NPs are in many cases harder to obtain than
compounds produced by chemical synthesis and are rarely
found in vendors’ catalogs, they are nonetheless a valuable
addition to screening libraries (11,13). Due to their com-
plex stereochemistry, they are oftenmore selective than syn-
thetic compounds and are particularly suitable–for address-
ing low-druggable targets (15,16). Furthermore, NPs are in
most cases produced enantiomerically pure, whereas enan-
tiomeric purification of synthetic compounds can be an ex-
pensive and exhausting task (17).
Due to the variety of chemical precursors and diversity
of produced scaffolds, streptomycetes are versatile hosts
for industrial heterologous expression (18). Developments
in biotechnology and synthetic biology have led to artifi-
cially minimized host strains that can be utilized for the
production of various compounds (19). For example, the
genetically engineered SUKA strains, descendants of the
industrial microorganism Streptomyces avermitilis, which
is already known for its highly efficient production of
the anthelmintic agent avermectin (20), have proven use-
ful as a heterologous host in the production of several sec-
ondary metabolites. Beyond the production of bioactive
compounds, the rich diversity of chemical scaffolds pro-
duced by streptomycetes enables their use as precursors
for many semi-synthetic approaches. For example, Strepto-
myces venezuelae has recently been employed as a producer
of bisabolenes (21), which are sesquiterpenes present in sev-
eral essential oils in plants. The advanced biofuel bisabolane
(22) is synthesized from them in a single step by chemical
hydrogenation (23).
Although StreptomeDB demonstrates that there are al-
ready thousands of compounds isolated from strepto-
mycetes, their potential as a source of NPs is far from ex-
hausted (24). Advancing methods still allow for the discov-
ery of new strains and compounds, such as the phenalino-
lactones, i.e. terpene glycosides with a rare, highly oxidized
 -butyrolactone structure (25).
The broad interest in streptomycetes has so far led to
more than 23 000 publications in PubMed. In the last years,
the number of publications per year was constantly growing
to reach about 1000 in 2014, stressing the need for an up-
dated StreptomeDB that makes this vast amount of data
accessible.
Here we present StreptomeDB 2.0, a major update with
an increase from about 2500 to over 4000 compounds, hun-
dreds of which required manual drawing prior to insertion
into the database, and more than 2500 host strains. Addi-
tionally, the introduced new features assist in the navigation
through the vast chemical diversity produced by strepto-
mycetes (Figure 1). This allows for a deeper understanding
of the complexity and evolution of the synthesis machinery




Manual curation of literature was carried out following the
protocol of the original database (11). For the sake of com-
pleteness, special focus was put on gathering compounds
from full texts. Additionally, hundreds of compounds with
name not provided in the referenced manuscript or not
found in PubChem were manually depicted prior to inser-
tion into the database.
Generation of the phylogenetic tree
The phylogenetic tree is based on the most common 16S
rRNA sequence per strain. Over 20 000 sequences from
freely available sources, such as silva (26) and ENA (27),
were filtered for integrity and length and mapped to organ-
isms in StreptomeDB. This resulted, in some cases, in over
150 different 16S rRNA sequences for a single strain. If it
was not possible to identify the best sequence, a hypotheti-
cal, most common sequence was derived. For this approach,
the strain-specific datasets were first scanned with BLAST+
(28) for the sequences that produce the most hits with an
E-value below 1 × 10−4 and a coverage over 97%. If this re-
sulted inmore than one sequence, a consensus sequence was
built with the dumb consensus function, as implemented
in Biopython (29). Sequences were aligned with ClustalW
(30). Phylogenetic analysis of the resulting alignment was
performed with theMEGA software package (31) using the
maximum likelihood and maximum parsimony algorithms,
eachwith 250 bootstrap replications. Sub-clusters in the tree
were detected by summarizing all leafs that have a common
ancestor node within range of 0.07 nt substitutions per side,
using the DendroPy library (32). The final editing and visu-
alization was done with the ETE 2 toolkit (33).
Gene clusters, genomes and taxonomy
If available, links to gene clusters in DoBISCUIT (34) or
MiBIG(35) are provided in StreptomeDB. Host organisms
are linked to freely available full genomes from GenBank
(36) and entries in the NCBI taxonomy database (37). Sub-
strains and mutants without taxonomy ID are linked to
their primary strains.
Scaffold-based molecular decomposition
The Scaffold Decomposition tool included in Canvas 2.3
(Schro¨dinger, LLC, New York, NY, USA) was used to pro-
cess molecules from StreptomeDB and extract all repre-
sented scaffolds. Small molecules can comprise one or more
level 0 scaffolds, i.e. root cyclic or polycyclic independent
structures. Two chemically equivalent or different level 0 en-
tities connected by an aliphatic or functionalized linker de-
fine a level 1 scaffold. Subunits composed of a level 0 plus a
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Prediction of fragmentation patterns in mass spectra
The software CFM-ID, based on competitive fragmenta-
tion modeling to produce a probabilistic generative model
for electrospray tandem spectrometry (ESI-MS/MS) frag-
mentation (39), was used to predict the fragmentation spec-
trum of molecules with ≤30 heavy atoms in positive ioniza-
tion mode at 10, 20 and 40 V, and assign the resulting peaks
to their chemical structure. For each intensity level, themost
intense peaks (max. 5) are reported in StreptomeDB.
Prediction of 1H and 13C NMR peaks
The nuclear magnetic resonance (NMR) Predictor tool, as
implemented in the command-line platform cxcalc (Marvin
15.4.13.0, 2015, ChemAxon, http://www.chemaxon.com),
was used to predict the 1H and 13C NMR spectra of all
molecules.
NEW FEATURES AND UPDATES
Phylogenetic tree
A new feature of StreptomeDB is the comprehensive phy-
logenetic tree based on 16S rRNA sequences. Considering
the usually similar six or more 16S rRNA (40) sequences
present in a Streptomyces genome (and in some cases sev-
eral similar sequencing attempts for one sequence, which
cannot be distinguished in quality or length), we generated
a consensus sequence for each strain. We have chosen a tree
based on 16S rRNA to achieve the highest possible cov-
erage of the data contained in StreptomeDB. For a better
overview and because of the relatively short evolutionary
distance, more than 1200 sub strains are represented by 340
parent stains, e.g. clicking on ‘Streptomyces griseus’ leads
to 128 compounds produced either by S. griseus itself or
one of its 58 sub strains, such as S. griseus or S. griseus var.
psychrophilus. The apparently small number of 340 shown
strains comprises more than two-thirds of the compounds
in the database, therefore indicating a good coverage of the
available molecules. Additionally, it is possible to access the
phylogenetic tree from any search, with the producing or-
ganisms of the related compounds highlighted. This pro-
vides the possibility to visualize the distribution of a cer-
tain scaffold, chemotype, compound, bioactivity or syn-
thetic route in an evolutionary context.
Scaffold-based navigation and search system
A new scaffold-based navigation has been integrated and
the compound search system has been substantially im-
proved. All molecules have been redefined bymeans of their
scaffold framework (38), and there is now the possibility to
browse through the gathered chemical scaffolds. At each
scaffold level (Search -> Scaffolds browser), the user can
choose one or several scaffolds, which are sorted by fre-
quency among the gathered compounds, and display either
compounds or higher-level scaffolds. A phylogenetic tree
with highlighted producing organisms can now be easily
accessed. Furthermore, compound cards contain a list of
represented scaffolds, which in turn link to a list of com-
pounds that contain the scaffold. This enables the bidi-
rectional browsing through the chemical diversity of the
database on a structural basis and its connection to the
evolution of the producing organisms. Table 1 shows that
StreptomeDB contains more than 1000 level 0 scaffolds and
hundreds of higher-level scaffolds, including 281 scaffolds
of very advanced framework and high molecular weight. In
addition, searches based on user-defined chemical structure
patterns can be performed taking advantage of fast sub-
structure searches (Search -> Compound(structure) sec-
tion).
Additional content
Compound cards now provide predicted MS and NMR
spectra for thousands of compounds. The MS/MS spectra
include the five most intensive peaks for 10, 20 and 40 V en-
ergy levels. The chemical structure of each peak is depicted.
NMR data are listed in a table that includes intensity, mul-
tiplicity and chemical shift for both, 1H and 13C NMR. It
is possible to query the database for any combination of 1H
and 13C signals or MS peaks. Additionally, there is the pos-
sibility to query the database by physicochemical properties,
including molecular weight, octanol/water partition coef-
ficient (clog Po/w), number of nitrogen and oxygen atoms
and stereogenic complexity, i.e. C*/CT (16). Finally, Strep-
tomeDB includes links to all publicly available gene clusters
and genomes for compounds and host organisms.
Back end and library updates
All software libraries related to the web page, its database
back end and the in-house curation platform were updated
to the latest versions. The structures of curated molecules
were mapped to canonical SMILES using ChemicalTool-
BoX (41). The update steps have been redesigned to upload
new molecules and related data to the database back end
automatically, based on the uniqueness of structures.
CONCLUSION AND FUTURE PROSPECTS
Here we present a major update on StreptomeDB, which
implements a series of new features to offer easier access to
the huge amount of data related to streptomycetes, which is
hidden in literature. Furthermore, StreptomeDB improves
the integration of this information in a chemical or evolu-
tionary context.
From a chemical point of view, the implementation of
a comprehensive scaffold-based navigation system enables
browsing the rich diversity of NPs produced by strepto-
mycetes. Scaffold-based molecular representations are a
prominent tool in medicinal chemistry (38) and allow for
classifying and comparing the coverage and content of
chemical libraries. We could identify hundreds of naturally
occurring level 1 scaffolds not found in purchasable com-
pounds (15). This is of particular interest in drug discovery,
as on average each commercialized drug contains a novel
scaffold, thus stressing the crucial relevance of mining both
natural sources and literature for molecules. Clearly, sec-
ondary metabolites produced by streptomycetes are an at-
tractive source of chemical diversity.
The phylogenetic tree enables the visualization of the dis-
tribution of these scaffolds and the compounds they rep-
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Table 1. Chemical diversity of StreptomeDB
Scaffold level No. of unique scaffolds Scaffold level No. of unique scaffolds
0 1,032 6 213
1 732 7 137
2 672 8 96
3 559 9 91
4 469 10 84
5 314 >10 281
Scaffold levels and the number of unique scaffolds included in the database.
strains, this feature offers an easy access to additional ref-
erences and background information of closely related or-
ganisms. It is a new approach toward the understanding of
the evolution of secondary metabolism. Together with the
offered gene clusters and genomes it provides all building
blocks for comparative genome analysis, reconstruction of
metabolic networks, or building a customized,more special-
ized phylogenetic tree. Motivated by the decreasing costs
andmassive efforts that are currently undertaken in genome
sequencing, the number of published genomes and gene
clusters is quickly increasing (42). Therefore, we are look-
ing forward to expanding these features to an even greater
extent.
We have also improved the characterization and querying
of compounds by including predicted MS and NMR data.
These techniques are widely used in structural determina-
tion of secondary metabolites, and we realized that a tool
for comparing experimental MS spectra with that of com-
pounds in the database would be extremely beneficial for
the users of StreptomeDB. Now this is possible by querying
the database with experimental peaks, either from MS or
NMRdetermination, to retrieve compounds withmatching
patterns.
Due to the increasing popularity of StreptomeDB, we
want to encourage users to contact us if they find missing
data or have optimization proposals.
In conclusion, StreptomeDB is a versatile platform for
the gathering of information for projects that deal with
streptomycetes. It stands out from other popular NP
databases with a broader focus, such as Supernatural II,
KNAPsACK or UNPD (1,2,3): built on top of a highly
networked structure, StreptomeDB facilitates exposing co-
herences between different data, such as scaffolds, activi-
ties or phylogenetic distribution. It offers an ideal starting
point and a vast amount of supplementary resources for the
discovery of new compounds, virtual screening campaigns,
biochemical engineering and cheminformatics.
AVAILABILITY
StreptomeDB is freely available, open to all users,
and has no login requirements. All compounds
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